06-19

2024

The innovative drug HZ-A-018 capsules of Hangzhou HealZen Therapeutics Co., Ltd has been approved for a pivotal single-arm Phase II clinical study

Hangzhou HealZen Therapeutics Co., Ltd recently announced that its independently developed Class 1 innovative drug, HZ-A-018 capsules (Bruton's tyrosine kinase inhibitor), has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, to conduct a pivotal single-arm Phase II clinical study for the monotherapy of relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).

06-19

2024

The innovative targeted protein degrader HZ-Q1070

B-cell lymphoma (BCM) is a heterogeneous lymphoproliferative disease originating from B-lymphocytes. Common subtypes of BCM in China include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL), etc.

05-25

2024

Sustained Capital Infusion and Thriving BD Transactions in the Targeted Protein Degradation

Targeted Protein Degradation (TPD) technology, as one of the emerging frontiers in the biopharmaceutical industry, has garnered significant attention. With the continuous maturation and application of this technology, related Business Development (BD) transactions have been heating up, presenting an encouraging market landscape. In recent years, the number of global TPD field BD transactions has shown a year-on-year increase, with biopharmaceutical enterprises and venture capital from various countries actively participating.

12-13

2023

[ASH 2023] HeaZen Therapeutics Showcases Its New Generation of High CNS-Penetrating BTK Inhibitor and Dual CK1ε & PI3Kδ Inhibitor at ASH with Remarkable Clinical Efficacy

The 65th Annual Meeting of the American Society of Hematology (ASH) took place from December 9th to 12th, 2023, in San Diego, USA. HeaZen Therapeutics's independently developed new generation BTK inhibitor, HZ-A-018, and the dual-target CK1ε/PI3Kδ inhibitor, HZ-H08905, presented their latest clinical research data at the conference through posters. The research covered areas such as B-cell lymphoma and T/NK-cell lymphoma, with the full abstracts available on the ASH official website.

11-29

2023

HealZen Therapeutics and Shanghai Institute of Materia Medica Announce Clearance of Investigational New Drug（IND）Application For New BTK Degrader HZ-Q1070 for the Treatment of Relapsed or Refractory B-cell Lymphoma

11-24

2023

ASH 2023 | Hangzhou HealZen Therapeutics to Present Latest Clinical Results from New Generation BTK Inhibitor HZ-A-018 and Dual CK1ε/PI3Kδ Inhibitor HZ-H08905